{"id":"3fb8564f-62dc-5600-8cb3-1419ad65d8d2","stable_key":"8c946991-97f0-55ee-8df0-00e67621962f:nad-plus-oral-formulation-plasma","predicate":"does_not_significantly_change","statement":"The same LNAD+ trial found unchanged plasma NAD while methyl-nicotinamide and 2PY increased.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"f1ec2f5e-5900-5509-a3dd-9e150ed20299","mechanism_event_label":"Blood compartments and breakdown products can move differently.","subject":{"id":"9cf73903-df6e-575d-aec2-9a3c67e2054a","slug":"lnad-plus-formulation","display_name":"LathMized NAD+ formulation","entity_type_key":"chemical_species"},"object":{"id":"2107182b-07f5-5fea-8583-44889dbc7376","slug":"human-plasma-nad","display_name":"Human plasma NAD concentration","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"f1ec2f5e-5900-5509-a3dd-9e150ed20299","stable_key":"8c946991-97f0-55ee-8df0-00e67621962f:nad-plus-oral-formulation-plasma-event","event_type":"observed_relationship","label":"Blood compartments and breakdown products can move differently.","description":"The same LNAD+ trial found unchanged plasma NAD while methyl-nicotinamide and 2PY increased.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"9cf73903-df6e-575d-aec2-9a3c67e2054a","slug":"lnad-plus-formulation","display_name":"LathMized NAD+ formulation","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"2107182b-07f5-5fea-8583-44889dbc7376","slug":"human-plasma-nad","display_name":"Human plasma NAD concentration","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"283ed24b-06a1-50aa-9281-df3bac6ce37e","slug":"nad-plus","display_name":"NAD+","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"b02a63e0-a972-53c5-8a3a-eea6b7578cd5","slug":"n1-methylnicotinamide","display_name":"N1-Methylnicotinamide","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Same five-day randomized trial; primary analysis n=50.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Catabolite concentration changes are consistent with metabolism but are not direct quantitative flux measurements or proof of intact uptake.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"NAD+ collection; molecular form, preparation, species, exposure and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"nad-plus","display_name":"NAD+","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Blood compartments and breakdown products can move differently.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Oral LNAD+ rapidly elevates whole blood intracellular NAD and metabolic flux without elevating plasma NAD: evidence from a randomized controlled trial. · 2026 · https://pubmed.ncbi.nlm.nih.gov/42530810/ · DOI 10.1007/s11357-026-02399-1","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"e4962b20-d544-5f81-849b-ac9470e81aa7","evidence_kind":"source_excerpt","locator":"Lines 316-322","start_line":316,"end_line":322,"excerpt":"## nad-plus-oral-formulation-plasma\nBlood compartments and breakdown products can move differently.\nThe same LNAD+ trial found unchanged plasma NAD while methyl-nicotinamide and 2PY increased.\nModel: Same five-day randomized trial; primary analysis n=50.\nLimitations: Catabolite concentration changes are consistent with metabolism but are not direct quantitative flux measurements or proof of intact uptake.\nEvidence access: Primary abstract\nOral LNAD+ rapidly elevates whole blood intracellular NAD and metabolic flux without elevating plasma NAD: evidence from a randomized controlled trial. · 2026 · https://pubmed.ncbi.nlm.nih.gov/42530810/ · DOI 10.1007/s11357-026-02399-1","model_system":"Same five-day randomized trial; primary analysis n=50.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"f59aa302-d463-5462-876f-e21e64861eac","stable_key":"import-8c946991-97f0-55ee-8df0-00e67621962f","title":"NAD+: compartmental supply, consumption and cross-nutrient mechanisms (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"9f5324d0d652c80ad630b3100e28ce34cd2ce260ea2e1324332a4262ce72ae09","revision_id":"0e07909c-e8bc-5950-bafc-61371d9d6412","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}